Member Info for Globetrotter184

Agree with you on this PI100. ".... no obvious material revenue streams." No use being first off the block in diagnostic test such as the Monkey Pox one if it is not followed up by tangible sales forecast but just generic bla bla bla. Hopes that the DHSC dispute will soon be resolved seem to me optimistic . My view is that it will drag on and on. In the meantime without any catalyst the SP will simply continue to falter. Not impossible to see SP fall to 1.00.

Don't blame M M's. The wide spread is symptomatic of the Market sensing that GGP will deliver many years down the line.. Next support level at 8.5p and a rights issue still a possibility.

With you there Kats

Kenny with NCYT there is no such thing as things moving "swiftly".

A balanced view Captain. with you on this.

You are right The Doo. BB chat is irrelevant. some contributors think that the BOD read the BB 24/7. Nothing of the sort. I do not expect any tangible news earliest next year. This month by month expectation of news simply adds to frustration. I am a holder believe in SAR but at the same time accepting the risks that come with this sort of investment. No doubt very promising products but absolutely no certainty or guarantees and quite a few hurdles yet to overcome.

PI a resounding NO.

" To solve the DHSC dispute quickly". Give me a break please. Suspicious of this account as well.

Captain .... experience over the past year or so has shown that the Novacyt's BOD does not care two hoots about whats said on BB. The BB is just a way of shareholders venting their feelings and getting it off their chest.The communication has been horrendous which is a pity for a company which held so much promise. In this case silence is not golden but detrimental to both existing shareholders and potential ones. No institutional interest.

Gunner, PH's agenda and priorities are diametrically opposed to the interests of individual shareholders. I do not expect any tangible news flow before late this year/early next year. Delays are the order of the day in this kind of investment and there are no guarantees. I hold and still believe in SAR however being firmly with feet on the ground and i try not to be over exuberant.

Lupus is not a game changer. The comments are positive in the wider general sense. More hurdles to overcome. Would not give the tweet , welcome as it may be, excessive importance.

Captain, i am with you on this. Company needs to concentrate on other revenue streams and be the first off the block. I am not convinced there is the ability to do so and competition must also be taken into consideration.

Potnak, in agreement with your more mundane and logical approach. Puts the prospects in the right perspective.

Feet on the ground guys. We have a long long way to achieve that billion market cap and never a clear pathway as there will be hurdles to overcome. Happy to wait some years if it happens.

BYP -its called accountability and regretfully Novacyt lacks it big time. The DHSC dispute was conveniently minimised ans camouflaged with RNS's to build up SP momentum. Investors hoodwinked.

Point taken Abery. Not being negative at all. Its in my character not to be over exuberant . I am a holder of the shares and hold because i believe in the prospects. But you are well aware of the pitfalls of the sector. Will not moan if i lose money but will jump for joy if i do like everybody else.

I admire your resilience and optimism Potnak. You give good vibes. However feet firmly on the ground as there is never a smooth pathway to success. Delays may occur and regulatory health authorities might not be totally on board with the clinical trials.

Karen, all very logical reasoning and calculations. However our recent past experience suggests that nothing is " easily achievable". I am currently not a holder of Nova and have been for some months trying to see to which level the SP can go down to. Not confident that the company has got its act right and too many "ifs and but's" for my liking.

Well said Yellow. Different revenue streams needed if this company wants to go forward.

Thanks Soder. A refreshingly sober and objective analysis of the state of affairs. DHSC issue will remain a drag on the valuation until resolved.